What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
GLP-1 / glucagon dual receptor agonist (IBI362 / LY3305677)
PeptideXpo primary owner
This PeptideXpo page is the primary SEO owner for buyers evaluating Mazdutide through broad supplier qualification, distributor assortment planning, OEM catalog coverage, and repeat-order economics. It should help the buyer decide whether this SKU belongs in a larger peptide sourcing program before specialist analytical or pharmacy documentation review.
Overview
Mazdutide (development codes IBI362 / LY3305677) is an investigational dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics in partnership with Eli Lilly. Unlike the GIP/GLP-1 dual agonist class (Tirzepatide) or the GIP/GLP-1/glucagon tri-agonist class (Retatrutide), Mazdutide engages only the GLP-1 and glucagon arms, without GIP, which positions it as a mechanistically distinct alternative for buyers studying glucagon-pathway pharmacology in isolation from GIP signaling. The molecule is in Phase 3 development in China for chronic weight management and type 2 diabetes, with regulatory approval signals expected on a faster timeline in the Chinese market than Western markets. PeptideXpo supplies Mazdutide acetate as a lyophilized powder at ≥99.0% HPLC purity with batch-specific COA. The analytical packet covers peak-integration HPLC, ESI mass spec, water content, and counter-ion; sequence verification by LC-MS/MS is available on request and recommended at first-time supplier qualification. The 10 mg standard fill size covers typical research aliquot work; larger fills for sustained-research programs are available through the OEM service.
Who buys this, and why
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Primary buyer fit: academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
Investigational compound in Phase 3 development (Innovent / Eli Lilly); not approved as a finished drug at the time of writing. Supplied for research use only. CAS commonly cited but should be verified per batch COA.
Frequently asked questions
All three are multi-receptor incretin-pathway peptides, but the receptor coverage differs: Tirzepatide is GIP + GLP-1, Mazdutide is GLP-1 + glucagon, Retatrutide is GIP + GLP-1 + glucagon. The presence or absence of the glucagon arm is the key mechanistic divider, adding glucagon receptor agonism contributes hepatic-energy-expenditure effects on top of the incretin-driven glycemic and weight effects. Mazdutide isolates the GLP-1 + glucagon mechanism, which is useful for research distinguishing the glucagon contribution from the GIP contribution within the dual / tri-agonist class. Buyers should not assume mechanistic equivalence between any pair of molecules in this class, the readouts differ enough to matter at the experimental-design level. See our [GLP-1 class comparison article](/insights/glp-1-class-comparison-tirzepatide-retatrutide-mazdutide-survodutide) for the full side-by-side.
Mazdutide is being developed by Innovent Biologics (China) under license from Eli Lilly, with the partnership reflecting Eli Lilly's strategy of licensing some metabolic-pipeline assets to regional partners for China-focused development while retaining global rights to its own pipeline assets like Retatrutide. The Mazdutide Phase 3 program (DREAMS-1 through DREAMS-3) has reported Phase 3 readouts on weight management and type 2 diabetes endpoints. Chinese regulatory approval is expected to precede Western approval by a meaningful margin, buyers in China can reference local NMPA-pathway documentation for the eventual approval; buyers elsewhere should treat Mazdutide as investigational until further notice.
Both target the same receptor pair (GLP-1R + GCGR, no GIP) and are mechanistically similar at the receptor-coverage level, so the choice between them depends on which sponsor's clinical data your research most needs to align with. Mazdutide (Innovent/Eli Lilly, China-focused development) is the appropriate choice for research benchmarking against Chinese clinical data. Survodutide (Boehringer Ingelheim/Zealand Pharma, global development) is the appropriate choice for benchmarking against EU/US clinical data. The peptide sequences and lipidation chemistries differ, confirm exact identity per batch COA before treating the two as interchangeable in any research context.
Related peptides
GLP-1 / glucagon dual receptor agonist (BI 456906)
GIP / GLP-1 / glucagon tri-agonist
GIP / GLP-1 dual receptor agonist
